{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:47:23Z","timestamp":1779378443475,"version":"3.53.1"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Center for Anti-Infective Research and Development"},{"DOI":"10.13039\/100030930","name":"Hartford Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The \u03b2-lactam\/\u03b2-lactamase inhibitor (BL\/BLI) combination drugs, ceftazidime\/avibactam, meropenem\/vaborbactam, and imipenem\/relebactam, have proven especially useful for treating carbapenemase-producing, carbapenem-resistant organisms (CRO), specifically Klebsiella pneumoniae carbapenemases (KPCs). However, non-KPC mechanisms of resistance are rising in prevalence among Gram-negatives and are increasingly challenging to treat. These newer BL\/BLIs, including sulbactam\/durlobactam, have an array of activity against mechanisms of carbapenem resistance beyond KPC and therefore play an important role in the treatment of non-KPC carbapenem-resistant organisms. This review, the second in a 2-part series, lays out the non-KPC attributes of the newer BL\/BLIs with a focus on clinical utility against Burkholderia cepacia complex, Stenotrophomonas maltophilia, Acinetobacter baumannii, and other rare pathogens.<\/jats:p>","DOI":"10.1093\/cid\/ciaf403","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T11:52:50Z","timestamp":1752925970000},"page":"411-419","source":"Crossref","is-referenced-by-count":2,"title":["Non-\n                    <i>Klebsiella pneumoniae<\/i>\n                    Carbapenemase Attributes of the Newer \u03b2-lactam\/\u03b2-lactamase Inhibitors, Part 2:\n                    <i>Burkholderia cepacia<\/i>\n                    Complex,\n                    <i>Stenotrophomonas maltophilia<\/i>\n                    , and\n                    <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5874-5174","authenticated-orcid":false,"given":"Andrew J","family":"Fratoni","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Gethers","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]},{"name":"Division of Infectious Diseases, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"2026031619514704800_ciaf403-B1","author":"CDC"},{"key":"2026031619514704800_ciaf403-B2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14787210.2024.2440018","article-title":"Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii","volume":"23","author":"Fu","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026031619514704800_ciaf403-B3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciae048","article-title":"Non-KPC attributes of newer beta-lactam\/beta-lactamase inhibitors, part 1: Enterobacterales and Pseudomonas aeruginosa","volume":"79","author":"Fratoni","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031619514704800_ciaf403-B4","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031619514704800_ciaf403-B5","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.8221.1","article-title":"Members of the genus Burkholderia: good and bad guys","volume":"5","author":"Eberl","year":"2016","journal-title":"F1000Res"},{"key":"2026031619514704800_ciaf403-B6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","article-title":"Antibiotic resistance in Burkholderia species","volume":"28","author":"Rhodes","year":"2016","journal-title":"Drug Resist Updat"},{"key":"2026031619514704800_ciaf403-B7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/cid\/cix559","article-title":"A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States Veterans Health Administration","volume":"65","author":"El Chakhtoura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026031619514704800_ciaf403-B8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.00954-06","article-title":"Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis","volume":"51","author":"Zhou","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fcimb.2011.00006","article-title":"Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia","volume":"1","author":"Loutet","year":"2011","journal-title":"Front Cell Infect Microbiol"},{"key":"2026031619514704800_ciaf403-B10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients","volume":"3","author":"Papp-Wallace","year":"2017","journal-title":"ACS Infect Dis"},{"key":"2026031619514704800_ciaf403-B11","doi-asserted-by":"crossref","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","article-title":"In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/mdr.2021.0353","article-title":"Susceptibility of Burkholderia cepacia complex to ceftazidime\/avibactam and standard drugs of treatment for cystic fibrosis patients","volume":"28","author":"Schaumburg","year":"2022","journal-title":"Microb Drug Resist"},{"key":"2026031619514704800_ciaf403-B13","doi-asserted-by":"crossref","first-page":"e01595","DOI":"10.1128\/AAC.01595-19","article-title":"In vitro activities of beta-lactam-beta-lactamase inhibitor antimicrobial agents against cystic fibrosis respiratory pathogens","volume":"64","author":"Caverly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B14","doi-asserted-by":"crossref","first-page":"e0133221","DOI":"10.1128\/AAC.01332-21","article-title":"Activity of imipenem-relebactam against multidrug- and extensively drug-resistant Burkholderia cepacia complex and Burkholderia gladioli","volume":"65","author":"Becka","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B15","doi-asserted-by":"crossref","first-page":"e00181","DOI":"10.1128\/JCM.00181-19","article-title":"Switching partners\u201d: piperacillin-avibactam is a highly potent combination against multidrug-resistant Burkholderia cepacia complex and Burkholderia gladioli cystic fibrosis isolates","volume":"57","author":"Zeiser","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026031619514704800_ciaf403-B16","doi-asserted-by":"crossref","first-page":"e01930","DOI":"10.1128\/AAC.01930-20","article-title":"In vitro antibacterial activity and in vivo efficacy of sulbactam-durlobactam against pathogenic Burkholderia species","volume":"65","author":"Papp-Wallace","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B17","doi-asserted-by":"crossref","first-page":"e02213","DOI":"10.1128\/AAC.02213-17","article-title":"Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam","volume":"62","author":"Tamma","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B18","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/jac\/dky136","article-title":"Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime\/avibactam plus aztreonam","volume":"73","author":"Barlow","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s15010-018-1261-y","article-title":"Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam","volume":"47","author":"Los-Arcos","year":"2019","journal-title":"Infection"},{"key":"2026031619514704800_ciaf403-B20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/jac\/dky558","article-title":"Use of ceftazidime\/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series","volume":"74","author":"Spoletini","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B21","doi-asserted-by":"crossref","first-page":"e13034","DOI":"10.1111\/tid.13034","article-title":"A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy","volume":"21","author":"Canton-Bulnes","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2026031619514704800_ciaf403-B22","doi-asserted-by":"crossref","first-page":"e13082","DOI":"10.1111\/tid.13082","article-title":"Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis","volume":"21","author":"Dacco","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2026031619514704800_ciaf403-B23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/1120009X.2019.1671654","article-title":"Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime\/avibactam plus trimethoprim\/sulfametoxazole for Bulkholderia cepacia reacutization","volume":"31","author":"Saffioti","year":"2019","journal-title":"J Chemother"},{"key":"2026031619514704800_ciaf403-B24","doi-asserted-by":"crossref","first-page":"ofaa051","DOI":"10.1093\/ofid\/ofaa051","article-title":"Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514704800_ciaf403-B25","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful treatment of bloodstream infection due to metallo-beta-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"2026031619514704800_ciaf403-B26","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/ofid\/ofaa439.1787","article-title":"1607. Dual therapy with aztreonam & ceftazidime\/avibactam against multi-drug resistant Stenotrophomonas maltophilia on tricuspid valve endocarditis","volume":"7","author":"Alexander","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514704800_ciaf403-B27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/FTD.0000000000000857","article-title":"Optimization of aztreonam in combination with ceftazidime\/avibactam in a cystic fibrosis patient with chronic Stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: a case study","volume":"43","author":"Cowart","year":"2021","journal-title":"Therapeutic Drug Monitoring"},{"key":"2026031619514704800_ciaf403-B28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.idnow.2021.01.014","article-title":"Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia","volume":"51","author":"Diarra","year":"2021","journal-title":"Infect Dis Now"},{"key":"2026031619514704800_ciaf403-B29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2026031619514704800_ciaf403-B30","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1093\/jac\/dkac304","article-title":"Trimethoprim\/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model","volume":"77","author":"Lasko","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B31","doi-asserted-by":"crossref","first-page":"e0216721","DOI":"10.1128\/aac.02167-21","article-title":"In vitro time-kill studies of trimethoprim\/sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli using cation-adjusted Mueller-Hinton broth and ISO-Sensitest broth","volume":"66","author":"Lasko","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B32","doi-asserted-by":"crossref","first-page":"e00405","DOI":"10.1128\/mBio.00405-19","article-title":"Population structure, molecular epidemiology, and beta-lactamase diversity among Stenotrophomonas maltophilia isolates in the United States","volume":"10","author":"Mojica","year":"2019","journal-title":"mBio"},{"key":"2026031619514704800_ciaf403-B33","first-page":"e00297","article-title":"Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B34","doi-asserted-by":"crossref","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"2026031619514704800_ciaf403-B36","doi-asserted-by":"crossref","first-page":"e12955","DOI":"10.1111\/tid.12955","article-title":"Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients","volume":"20","author":"Farfour","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2026031619514704800_ciaf403-B37","author":"Agency","year":"2016"},{"issue":"Suppl 7","key":"2026031619514704800_ciaf403-B38","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026031619514704800_ciaf403-B39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026031619514704800_ciaf403-B40","doi-asserted-by":"crossref","first-page":"e0298577","DOI":"10.1371\/journal.pone.0298577","article-title":"In vitro activity of ceftazidime\/avibactam, cefiderocol, meropenem\/vaborbactam and imipenem\/relebactam against clinical strains of the Stenotrophomonas maltophilia complex","volume":"19","author":"Mendez-Sotelo","year":"2024","journal-title":"PLoS One"},{"key":"2026031619514704800_ciaf403-B41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.medmal.2020.01.003","article-title":"Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone","volume":"50","author":"Moriceau","year":"2020","journal-title":"Med Mal Infect"},{"key":"2026031619514704800_ciaf403-B42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","article-title":"In vitro activities of cefiderocol, ceftolozane\/tazobactam, ceftazidime\/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan","volume":"74","author":"Hsueh","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12866-021-02108-2","article-title":"Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Microbiol"},{"key":"2026031619514704800_ciaf403-B44","doi-asserted-by":"crossref","first-page":"e00777","DOI":"10.1128\/AAC.00777-17","article-title":"Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam","volume":"61","author":"Mojica","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B45","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1099\/jmm.0.000801","article-title":"In vitro activity of beta-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis","volume":"67","author":"Mathy","year":"2018","journal-title":"J Med Microbiol"},{"key":"2026031619514704800_ciaf403-B46","doi-asserted-by":"crossref","first-page":"e01433","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B47","doi-asserted-by":"crossref","first-page":"e01426","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-beta-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B48","doi-asserted-by":"crossref","first-page":"e00010","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-\u03b2-lactamase-producing gram-negative bacteria","volume":"63","author":"Emeraud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B49","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-beta-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026031619514704800_ciaf403-B50","author":"FDA"},{"key":"2026031619514704800_ciaf403-B51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026031619514704800_ciaf403-B52","doi-asserted-by":"crossref","first-page":"114999","DOI":"10.1016\/j.diagmicrobio.2020.114999","article-title":"OXA-23 and OXA-40 producing carbapenem-resistant Acinetobacter baumannii in Central Illinois","volume":"97","author":"Koirala","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026031619514704800_ciaf403-B53","doi-asserted-by":"crossref","first-page":"e0082822","DOI":"10.1128\/aac.00828-22","article-title":"Structural basis of PER-1-mediated cefiderocol resistance and synergistic inhibition of PER-1 by cefiderocol in combination with avibactam or durlobactam in Acinetobacter baumannii","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B54","doi-asserted-by":"crossref","first-page":"e0078122","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B55","doi-asserted-by":"crossref","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-Reville","year":"2017","journal-title":"Nat Microbiol"},{"key":"2026031619514704800_ciaf403-B56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cmi.2024.10.012","article-title":"Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates","volume":"31","author":"Le Terrier","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026031619514704800_ciaf403-B57","doi-asserted-by":"crossref","first-page":"ofac492.023","DOI":"10.1093\/ofid\/ofac492.023","article-title":"732. Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections","volume":"9","author":"Altarac","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514704800_ciaf403-B58","doi-asserted-by":"crossref","first-page":"e0162724","DOI":"10.1128\/aac.01627-24","article-title":"A microbiological and structural analysis of the interplay between sulbactam\/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp","volume":"69","author":"Veeraraghavan","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B59","doi-asserted-by":"crossref","first-page":"e01025","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter infections and treatment options","volume":"64","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B60","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3390\/microorganisms9122473","article-title":"In vitro activity of 22 antibiotics against Achromobacter isolates from people with cystic fibrosis. Are there new therapeutic options?","volume":"9","author":"Beauruelle","year":"2021","journal-title":"Microorganisms"},{"key":"2026031619514704800_ciaf403-B61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12941-024-00709-z","article-title":"Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains","volume":"23","author":"Jean-Pierre","year":"2024","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026031619514704800_ciaf403-B62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/dky423","article-title":"In vitro activity of seven beta-lactams including ceftolozane\/tazobactam and ceftazidime\/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients","volume":"74","author":"Massip","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B63","doi-asserted-by":"crossref","first-page":"e0254121","DOI":"10.1128\/jcm.02541-21","article-title":"Antimicrobial susceptibility of Elizabethkingia species: report from a reference laboratory","volume":"60","author":"Comba","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026031619514704800_ciaf403-B64","doi-asserted-by":"crossref","first-page":"ofad014","DOI":"10.1093\/ofid\/ofad014","article-title":"Characterization of a novel pathogen in immunocompromised patients: Elizabethkingia anophelis-exploring the scope of resistance to contemporary antimicrobial agents and beta-lactamase inhibitors","volume":"10","author":"Yasmin","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514704800_ciaf403-B65","doi-asserted-by":"crossref","first-page":"e01963","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-beta-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B66","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkac446","article-title":"In vivo pharmacokinetic\/pharmacodynamic evaluation of cefepime\/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model","volume":"78","author":"Abdelraouf","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkab405","article-title":"Clinical exposure-response relationship of cefepime\/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model","volume":"77","author":"Lasko","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B68","doi-asserted-by":"crossref","first-page":"ofac492.022","DOI":"10.1093\/ofid\/ofac492.022","article-title":"731. CERTAIN-1: a phase 3 study of cefepime-taniborbactam efficacy and safety in the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP)","volume":"9","author":"McGovern","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026031619514704800_ciaf403-B69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jac\/dkaa391","article-title":"Activity of beta-lactam\/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B70","doi-asserted-by":"crossref","first-page":"dlae060","DOI":"10.1093\/jacamr\/dlae060","article-title":"In vitro activity of cefepime\/taniborbactam and comparator agents against Gram-negative bacterial bloodstream pathogens recovered from patients with cancer","volume":"6","author":"Gerges","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026031619514704800_ciaf403-B71","first-page":"149","article-title":"Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model","volume":"75","author":"Kidd","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B72","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1093\/jac\/dkac280","article-title":"Activity of ertapenem\/zidebactam (WCK 6777) against problem Enterobacterales","volume":"77","author":"Mushtaq","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B73","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/jac\/dkac110","article-title":"In vivo efficacy of WCK 6777 (ertapenem\/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model","volume":"77","author":"Gethers","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B74","doi-asserted-by":"crossref","first-page":"e02596","DOI":"10.1128\/AAC.02596-17","article-title":"In vivo efficacy of meropenem with a novel non-beta-lactam-beta-lactamase inhibitor, nacubactam, against gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model","volume":"62","author":"Monogue","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B75","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/jac\/dkad033","article-title":"Development of an optimized and practical pharmacokinetics\/pharmacodynamics analysis method for aztreonam\/nacubactam against carbapenemase-producing K. pneumoniae","volume":"78","author":"Igarashi","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026031619514704800_ciaf403-B76","doi-asserted-by":"crossref","first-page":"105838","DOI":"10.1016\/j.ijantimicag.2019.10.019","article-title":"Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model","volume":"55","author":"Asempa","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026031619514704800_ciaf403-B77","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s11095-023-03608-8","article-title":"In vivo pharmacokinetic\/pharmacodynamic analysis of the efficacy of the cefepime\/nacubactam combination against beta-lactamase-producing Enterobacterales based on the instantaneous MIC concept","volume":"40","author":"Igarashi","year":"2023","journal-title":"Pharm Res"},{"key":"2026031619514704800_ciaf403-B78","doi-asserted-by":"crossref","first-page":"106330","DOI":"10.1016\/j.ijantimicag.2021.106330","article-title":"Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel beta-lactamase inhibitor, nacubactam, against carbapenem-resistant and\/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model","volume":"57","author":"Hagihara","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2026031619514704800_ciaf403-B79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgar.2022.07.006","article-title":"In vitro and in vivo activities of a novel beta-lactamase inhibitor combination imipenem\/XNW4107 against recent clinical Gram-negative bacilli from China","volume":"31","author":"Li","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2026031619514704800_ciaf403-B80"},{"key":"2026031619514704800_ciaf403-B81","doi-asserted-by":"crossref","first-page":"e0130421","DOI":"10.1128\/AAC.01304-21","article-title":"In vitro activity of ceftibuten\/VNRX-5236 against urinary tract infection isolates of antimicrobial-resistant Enterobacterales","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B82","doi-asserted-by":"crossref","first-page":"e0134622","DOI":"10.1128\/aac.01346-22","article-title":"In vitro activity of ceftibuten-avibactam against beta-lactamase-positive Enterobacterales from the ATLAS global surveillance program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026031619514704800_ciaf403-B83","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s40121-021-00509-4","article-title":"Oral antibiotics in clinical development for community-acquired urinary tract infections","volume":"10","author":"Veeraraghavan","year":"2021","journal-title":"Infect Dis Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf403\/63810841\/ciaf403.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/411\/63810841\/ciaf403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/411\/63810841\/ciaf403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:52:10Z","timestamp":1773705130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/3\/411\/8209803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf403","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,7,21]]}}}